Navigation Links
Patients at risk of knee joint complications when new technology is used
Date:12/14/2011

Orthopaedic surgeons face a steep learning curve to get used to new prostheses, and the instruments and methods that go with them, before new total knee replacement procedures are as safe and effective as conventional methods. Patients who undergo the first 15 operations using a new device in a hospital are 48 percent more likely to need early revision surgery, than patients undergoing an operation to fit a prosthesis previously used in the hospital. The work by Mikko Peltola from the National Institute for Health and Welfare in Finland, and colleagues, is published online in Springer's journal, Clinical Orthopaedics and Related Research.

Total knee arthroplasty, or replacement, is an established treatment for patients with severe osteoarthritis of the knee. There are numerous brands and models of endoprostheses (a prosthesis used internally) available and new models continue to emerge as a result of a combination of new technology, marketing efforts and the increasing number of patients requiring the surgery.

Hospital staff makes important decisions when choosing the implants and instruments they use, and these decisions carry consequences for patients' health. According to the research team, however, new equipment and techniques are often used in clinical practice, occasionally without evidence of effectiveness and safety.

Peltola and team looked at the risk of early revision surgery following the introduction of a new endoprosthesis model for total knee arthroplasty. They studied data from the Finnish Arthroplasty Register to identify centers that had performed total knee replacement operations for primary osteoarthritis between 1998 and 2004. Of the 23,707 total number of patients who underwent the surgical procedure, 22,551 were followed up for five years.

The researchers found that the introduction of an endoprosthesis model in a hospital put the first patients at greater risk of revision surgery. The effect was
'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ACR in Choosing Wisely campaign to promote wise use of resources among physicians and patients
2. Statins may reduce mortality in patients hospitalized with influenza
3. Some muscular dystrophy patients at increased risk for cancer
4. HIV drug reduces graft-versus-host disease in stem cell transplant patients, Penn study shows
5. AML patients have high response rate with vorinostat added to treatment
6. Cancer Outpatients at Greater Risk for Blood Clots
7. Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkins lymphoma
8. Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma
9. Penn researchers repair immune system in leukemia patients following chemotherapy
10. Novel experimental agent is highly active in CLL patients, interim study shows
11. Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 2015 Thousands of aesthetic industry professionals ... sponsored by the American Society for Aesthetic Plastic Surgery ... was Zeltiq, the parent company of one of the ... With blazing growth, the one-of-a-kind device just sold its ... is currently in the news for gaining the FDA’s ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... ROTHWELL, Australia (PRWEB) May 30, 2015 At ... the rewards of vibrant health , which she attributes ... personally tested principles of good nutrition with the release of ... ” (published by Xlibris AU). , “Cook for Health and ... using natural, nutritious and mostly organic food . It ...
(Date:5/30/2015)... San Francisco, CA (PRWEB) May 30, 2015 ... San Francisco, California, is proud to announce their June ... a featured apartment community in San Francisco, Key Housing ... find quality housing in what is one of the ... Francisco is a plum posting, and understandably anyone who ...
(Date:5/30/2015)... Nevada (PRWEB) May 30, 2015 Venus ... of acne scars, large pores, deep wrinkles, stretch marks, ... licensed medical professional, such as Dr. F. Victor Rueckl ... of the clinical trials in Las Vegas. This body ... technology into a system that delivers proven results through ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... affordable protease inhibitor for patients in developing countries ... MYL ) today announced that Matrix Laboratories ... a 71.5% controlling interest, received the first and ... Tablets, 200 mg/50 mg. Matrix,s version of this ...
... healthcare professionals demonstrating exceptional service, sacrifice and innovation ... ANGELES, Feb. 25 Beginning March 1, 2009, ... Inspired Comfort Awards program. Since 2003, the ... awarded more than 70 outstanding healthcare professionals for ...
... the Leader in Technology-Enabled Telehealth Solutions, Adds Accomplished Financial Executive to ... ... 25, 2009 -- American TeleCare, Inc. (ATI) announced that Michael A. ... is the leader in the development and application of video-based telehealth ...
... (NYSE Alternext US: FIT), a leading provider of integrated ... conference call to discuss its financial results for the ... call is scheduled for 5:00 p.m. ET on Wednesday, ... 643-0580 to access the conference call, or can listen ...
... meal delivery offering to over 30,000 MembersNew Agreement ... Partnership within the new Fitness Industry Sales ChannelFORT ... DIET ), and Diversified Health & Fitness, ... together to promote eDiets, award-winning, fresh-prepared diet meal ...
... Feb. 25 The Quantum Group, Inc. (NYSE Amex: ... Services Organization (HSO), announced today that Senior Vice President ... scheduled to present at the 5th Annual Winter Technology ... is scheduled for 10:30 AM (pacific standard time) on ...
Cached Medicine News:Health News:Mylan's Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor 2Health News:Cherokee Inspired Comfort Awards Program Call for Nominations 2Health News:Cherokee Inspired Comfort Awards Program Call for Nominations 3Health News:American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer 2Health News:American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer 3Health News:eDiets.com(R) and Diversified Health & Fitness Announce New Strategic Marketing Partnership 2Health News:eDiets.com(R) and Diversified Health & Fitness Announce New Strategic Marketing Partnership 3Health News:eDiets.com(R) and Diversified Health & Fitness Announce New Strategic Marketing Partnership 4Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 2Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 3Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 4
(Date:5/29/2015)... , May 29, 2015 LifeNet Health ... total hiring for 2015 to more than 160 people. ... increased demand for LifeNet Health,s innovative bio-implants, which are ... more patients to be served. It also is a ... industry. "The growth and success of LifeNet ...
(Date:5/29/2015)... Mass. , May 29, 2015  Haemonetics Corporation ... Davies , Chief Operating Officer, will present at the ... York on June 23 rd , 2015 ... may access Mr. Davies, presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
... 49th American Society of ... Hematology Meeting, ... in a pivotal study of patients with indolent,non-Hodgkin,s lymphoma (NHL), whose ... induced a,high rate of response. TREANDA(R) is a novel investigational chemotherapy.,According ...
... HAYWARD, Calif., Dec. 8 Kosan Biosciences,Incorporated ... from a dose-escalating,Phase 1b clinical trial of ... (Velcade(R)), showing durable antitumor,activity and tolerability in ... following treatment with multiple conventional,therapies. The data ...
Cached Medicine Technology:TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 2Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 3Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 4Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 5Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: